Access PROSTOX Testing
PROSTOXTM Testing Access
To help prostate cancer patients avoid toxicity
Radiation treatment is a very effective treatment for prostate cancer. However, 15-20% of men will experience side effects that may start 3 months or later after treatment, with the most common side effects affecting the urinary system. These side effects are referred to as late genitourinary (GU) toxicity.
PROSTOX can predict an increased risk of late GU toxicity from specific radiation therapies:
PROSTOX ultra
- For stereotactic body radiotherapy (SBRT) which consists of 5-7 high doses of radiation to the prostate usually given over 10 days
PROSTOX CFRT
- For conventionally fractionated radiotherapy (CFRT) which consists of 35-45 small doses of radiation to the prostate given over 8-10 weeks
Knowing your risk of late GU toxicity can allow you and your doctor to choose the safest course of treatment for you.
PROSTOXTM Testing
Testing by MiraDX, patient access through MiraKind.
You are eligible to obtain PROSTOX testing through MiraKind if you:
- Have a prostate cancer diagnosis
- Have not received radiation therapy to the prostate
- Agree to participate in our research
Also, you must be considering one or both of these types of radiation therapy to the prostate:
- SBRT, 5-7 sessions over 10 days
- CFRT, 35-45 sessions over 8-10 weeks
$500* for each test
or $900* for both tests
*This discounted cost for PROSTOX testing is only available through MiraKind. Currently, testing access is not available for New York state residents.
Questions? Read our PROSTOX FAQ or Contact us
Understanding your PROSTOX results
Once your results are ready, you will need to discuss them with a physician.
PROSTOX ultra
- If a patient is found to be High Risk, they have a ~75% chance of developing late GU toxicity from SBRT to the prostate, whereas if they are Low Risk they have less than a 5% risk.1,2
PROSTOX CFRT
- If a patient is found to be High Risk, they have a ~72% chance of developing late GU toxicity from CFRT to the prostate, whereas if they are Low Risk they have less than a 7.5% risk.3
Questions? Read our PROSTOX FAQ or Contact us
Frequently asked questions about MiraDX PROSTOXTM testing through MiraKind
General questions about PROSTOX
Accessing PROSTOX through MiraKind
Taking the test
Participating in our research registry
Disclosure: Any discussion of medical management options is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
References
- Kishan AU, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Network Open 2019;2:e188006.
- Weidhaas, JB, et al. MicroRNA-based biomarkers of the radiation response in prostate cancer. Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 163-163. DOI: 10.1200/JCO.2020.38.6_suppl.163.
- Kishan AU, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Journal for Radiotherapy and Oncology 2022;167:226-232. doi: 10.1016/j.radonc.2021.12.040.
- Kishan AU, Marco N, Ma TM, Steinberg ML, Sachdeva A, Cao M, Ballas LK, Rietdorf E, Telesca D, Weidhaas JB. Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. Clin Transl Radiat Oncol. 2023 Feb 8;39:100594. doi: 10.1016/j.ctro.2023.100594. PMID: 36880064; PMCID: PMC9984404.
